BUZZ - Leerink says concerns over growth in the medical technology sector may overshadow third-quarter performance
路透社2026/10/09 13:06October 9 – Leerink Partners stated that, ahead of the third-quarter earnings reports, it remains cautious on the medical technology sector and pointed out that the short-term market environment is “somewhat uncertain.” The firm noted increasing competition in some markets, including the cardiac devices and diabetes care sectors; uncertainty in surgical volumes amid rising costs; weak consumer confidence; and pressure on hospital budgets due to higher interest rates. “We believe that even if third-quarter results are positive, they may be overshadowed by ongoing market concerns about profitability and growth prospects for 2027 and beyond,” the broker said. The firm believes that positive factors for specific companies could help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry during these sector-wide headwinds. The broker said it remains most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O), as a slowdown in adoption and intensifying competition may lead to lowered expectations for 2027. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translation may contain errors or fail to capture the required context, Reuters does not guarantee the accuracy of automated translation texts, and they are provided merely for readers’ convenience. Reuters accepts no liability for any damage or loss resulting from the use of automated translation features.)
October 9 - ** Leerink Partners stated that they remain cautious on the medical technology sector ahead of third-quarter earnings reports, and indicated that the market environment appears “somewhat uncertain” in the short term.
** The institution pointed out that competition is intensifying in some markets (including the cardiac devices and diabetes care sectors); there is uncertainty around surgery volumes amid rising costs; consumer confidence is weak; and rising interest rates are putting pressure on hospital budgets.
** “We believe that even positive third-quarter performances could be overshadowed by ongoing concerns about profitability and growth prospects in 2027 and beyond,” the brokerage said.
** The institution believes that company-specific positive factors may help Medtronic (MDT.N) and Tandem Diabetes Care (TNDM.O) outperform the broader industry amid overall sector headwinds.
** The brokerage said it is most cautious on PROCEPT BioRobotics (PRCT.O) and Insulet (PODD.O) because slower adoption rates and increased competition could lead to downward revisions of 2027 expectations.
(To assist non-native English speakers, Reuters has automated the translation of its reports into several other languages. Because automated translation may be inaccurate or lack essential context, Reuters does not guarantee the accuracy of the automated translation and provides it for reader convenience only. Reuters assumes no responsibility for any damage or losses arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ruanyun Edai gets Nasdaq notice after shares trade below $1 for 30 days
Ruanyun Edai received a Nasdaq notice for failing the $1.00 minimum bid price rule following 30 consecutive business days below $1. The deficiency period ran from Aug. 25 through Oct. 6, 2026, breaching Nasdaq Capital Market Listing Rule 5550(a)(2). A 180-day compliance window runs to April 5, 2027; compliance requires at least $1.00 for 10 consecutive business days. The notice does not immediately affect the stock’s Nasdaq listing or trading. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ruanyun Edai Technology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610091720PRIMZONEFULLFEED9843090) on October 09, 2026, and is solely responsible for the information contained therein.
BUZZ-CCC Intelligent Solutions stock surges on acquisition rumors
On October 9th, CCC Intelligent Solutions Holdings (CCC.O), a provider of automotive insurance software, saw its stock price rise by 9.5% in after-hours trading to $7.69. According to Bloomberg, GTCR and Elliott Investment Management are in advanced talks to acquire CCC, sources revealed. The report stated that the deal could be announced as soon as next week. However, the parties have not yet reached a final agreement, and details, including the timeline, may change; negotiations could end without a deal. CCC, GTCR, and Elliott have not immediately responded to Reuters’ requests for comment. CCC’s stock price has dropped about 12% so far this year. (For the convenience of non-English speakers, Reuters provides automated translations of its reports in several languages. As automated translations might be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of these texts and disclaims any liability for damages or losses arising from their use.)
Mynd.ai clarifies CEO Bin Shen joins board effective Oct. 12
Mynd.ai amended its Oct. 8 Form 6-K to correct its executive transition disclosure. The amendment added that newly appointed Chief Executive Officer and Interim Chief Financial Officer Bin Shen also joined the board effective Oct. 12, 2026. The filing also added an incorporation-by-reference section covering the company’s Form S-8 and Form F-3 registration statements. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mynd.Ai Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708441-26-000109), on October 09, 2026, and is solely responsible for the information contained therein.
Saudi Aramco resumes full oil supply to European customers, reducing alternative procurement pressure for European refineries
Saudi Aramco has announced that it will resume supplying full crude oil volumes to European refiners in November. Previously, after an attack by drones on Saudi Arabia’s East-West oil pipeline, Saudi Aramco had informed European clients that it would not provide any crude oil quotas in October, forcing buyers to seek alternative sources. The pipeline’s capacity has now been restored to over 80%, and Saudi Arabia’s daily crude oil exports to Europe, about 700,000 to 800,000 barrels, are expected to return to normal.
Crypto prices
More
